Charles River Laboratories International, Inc. logo CRL - Charles River Laboratories International, Inc.

Price: -- -- | CONSENSUS: Buy DETAILS
STRONG
BUY
1
BUY 25
HOLD 11
SELL 0
STRONG
SELL
0
| PRICE TARGET: $230.78 DETAILS
HIGH: $260.00
LOW: $213.00
MEDIAN: $220.00
CONSENSUS: $230.78
UPSIDE: 5.19%

About Charles River Laboratories International, Inc. (https://www.criver.com)

Charles River Laboratories International, Inc. operates as a contract research organization (CRO), providing essential preclinical services to the pharmaceutical and biotechnology industries. Its core business revolves around assisting clients with drug discovery, non-clinical development, and thorough safety testing, with its services extending globally across the United States, Europe, Canada, and the Asia Pacific region. The company organizes its diverse offerings into three principal segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions. 1. Research Models and Services (RMS): This division is a key supplier of high-quality rodent research models, including specially bred strains of rats and mice for experimental purposes. It also offers a comprehensive array of support services to help clients effectively utilize these models in their research and for the screening of potential non-clinical drug candidates. These include providing genetically engineered models, insourcing solutions for facility management, and diagnostic services for research animals. 2. Discovery and Safety Assessment (DSA): The DSA segment plays a crucial role in advancing early-stage drug pipelines. It delivers early-phase and in vivo discovery services focused on identifying and validating new therapeutic targets, chemical compounds, and antibodies. The ultimate goal is to prepare promising non-clinical drug and therapeutic candidates for subsequent safety evaluations. Additionally, this segment provides an extensive range of safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism studies, and pharmacokinetics. 3. Manufacturing Solutions: This segment addresses critical quality control requirements by offering in vitro methods for both routine and rapid testing of the quality of sterile and non-sterile pharmaceuticals, as well as consumer products. It also serves as a vital provider of specialized biologics testing, which is often outsourced by pharmaceutical and biotechnology companies. Furthermore, the segment supplies avian vaccine services, including specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products, all essential for vaccine production. Beyond these specialized segments, Charles River also manages contract vivarium operations, providing crucial animal housing and care facilities for its biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.

Key Executives

NAME TITLE DOB SALARY
Birgit Girshick CEO & Director 1970 $1,774,768 USD
Joseph W. LaPlume Corporate Executive Vice President of Corporate Development & Strategy 1974 $1,252,886 USD
Victoria L. Creamer Corporate Executive Vice President & Chief People Officer 1970 $1,225,929 USD
Glenn G. Coleman Corporate Executive Vice President & Chief Financial Officer 1968 $930,201 USD
Michael Gunnar Knell Corporate Senior Vice President & Chief Accounting Officer 1977 $912,225 USD
Amy Cianciaruso Corporate Senior Vice President, Chief Communications Officer & Government Relations
Brian F. Bathgate Corporate Senior Vice President of European Safety Assessment 1960
Julie Frearson Corporate Senior Vice President & Chief Scientific Officer
Kerry Dailey Corporate Senior VP & Chief Legal Officer
Mark Mintz Corporate EVP, Chief Information Officer & Global Shared Services 1974
Todd Spencer Corporate Vice President of Investor Relations

Company Peers

Peer analysis pending, check back in 1-2 minutes.